| Revenue growth | 41% YoY in FY26. |
|---|---|
| Margins | EBITDA margin 20.3%; PAT margin 14%; target 20-22% EBITDA for FY27. |
| Order book | 718+ clients; 98% retention rate; new orders for Quick Snap format. |
| Demand visibility | Strong visibility in nutraceuticals driving facility expansion. |
| Management confidence | High; confident in maintaining 14% PAT margins. |
Growth
FY26 Revenue up 41% to ₹146cr; EBITDA up 32% to ₹29.9cr; PAT grew to ₹20.5cr (14% margin).
Outlook
Guidance of 25-30% minimum growth for FY27; long-term target of ₹500cr revenue by FY29.
Risks
Raw material price volatility in solvents/packaging and potential lag in passing costs to customers.
Earnings Call filed with NSE, NSE: INFLUX. Summary written with AI assistance from the document.
Influx Healthtech Ltd: key numbers
- Share price
- ₹281.45
- Market cap
- ₹651.6 Cr
- Revenue (annual)
- ₹146.8 Cr
- Net profit (annual)
- ₹20.54 Cr
- P/E (TTM)
- 31.7×Sector 50.4×
- Promoter holding
- 73.53%
- FII holding
- 0.16%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Influx Healthtech Ltd
All →Influx Healthtech Legal & Regulatory
NSE imposed a fine of Rs. 1.83 Lakhs on Influx Healthtech for a delay in submitting consolidated financial results for the half year ended March 31, 2026.
- Value
- ₹0.02 Cr
Influx Healthtech Annual General Meeting
Influx Healthtech Limited held its 6th Annual General Meeting on September 18, 2026. The company transacted the business items as per the AGM notice.
Influx Healthtech Other Announcement
Influx Healthtech dispatched letters to shareholders without registered emails with the FY 2025-26 Annual Report weblink and 6th AGM notice. The letters are sent under Regulation 36(1)(b) of the SEBI Listing Regulations.
Influx Healthtech Earnings Call: Key Takeaways
Influx Healthtech delivered strong 41% YoY revenue growth in H2 FY26, driven by nutraceuticals, despite margin pressure from aggressive hiring ahead of massive capacity expansion.
Influx Healthtech Earnings Call: Key Takeaways
Influx Healthtech delivered strong FY26 performance as a specialist CDMO in nutraceuticals and cosmetics, focusing on capacity expansion and new technology implementation following its 2025 NSE listing.
Influx Healthtech H2 FY26 Results: Net Profit ₹10.5 Cr, Up 36.4% YoY
Influx Healthtech Ltd reported revenue from operations of ₹80.1 Cr (+41.0% YoY) and net profit of ₹10.5 Cr (+36.4% YoY) for H2 FY26.
- Key figure
- Net profit ₹10.5 Cr · +36.4% YoY